Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.

External advisors to the U.S. Food and Drug Administration will meet on Sept. 17 to consider data from Pfizer and BioNTech in support of booster shots. Meanwhile, a timeline is being presented on the authorization of Covid-19 vaccines for children.

U.S. Food and Drug Administration scientists said on Sept. 15 that booster doses of Pfizer’s Covid-19 vaccine may not be needed, even though the third shot generates a higher immune response in recipients.

Additional Covid-19 vaccine booster shots are not needed for the general population, leading scientists including two departing senior U.S. Food and Drug Administration officials and several from the World Health Organization (WHO) said in an article published in a medical journal on Sept. 13.

Pfizer Inc. on Aug. 25 said a booster dose of the company’s two-shot Covid-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the drugmaker seeks U.S. regulatory approval for a third injection.

A third dose of Pfizer’s Covid-19 vaccine significantly improved protection from infection and serious illness among people aged 60 and older in Israel compared with those who received two shots, findings published by the Health Ministry showed on Aug. 22.

Ion channels may be the Achilles’ heel of the SARS-CoV-2 virus, with research emerging from Israel that identified eight already-approved compounds that inhibit the activity of the E-protein channels in the virus’ membrane.

The U.S. Food and Drug Administration authorized a third dose of Covid-19 vaccines by Pfizer-BioNTech and Moderna for people with compromised immune systems.

Drugmakers Pfizer, BioNTech and Moderna are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

The U.S. Food and Drug Administration is expected to announce that the regulatory agency is authorizing the use of a booster shot for the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines in some immunocompromised patients.